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Among Outpatients With Coronary Artery Disease
Insights From the National Cardiovascular Data Registry
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Paul S. Chan, MD, MSC*‡
Kansas City, Missouri; Washington, DC; New York, New York; Rochester, Minnesota;
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Objectives This study examined the association between insurance status and physicians’ adherence with providing
evidence-based treatments for coronary artery disease (CAD).
Methods Within the PINNACLE (Practice Innovation and Clinical Excellence) registry of the NCDR (National Cardiovascular
Data Registry), the authors identified 60,814 outpatients with CAD from 30 U.S. practices. Hierarchical modified
Poisson regression models with practice site as a random effect were used to study the association between
health insurance (no insurance, public, or private health insurance) and 5 CAD quality measures.
Results Of 60,814 patients, 5716 patients (9.4%) were uninsured and 11,962 patients (19.7%) had public insurance,
whereas 43,136 (70.9%) were privately insured. After accounting for exclusions, uninsured patients with CAD
were 9%, 12%, and 6% less likely to receive treatment with a beta-blocker, an angiotensin-converting enzyme
inhibitor/angiotensin II receptor blocker (ACE-I/ARB), and lipid-lowering therapy, respectively, than privately in-
sured patients, and patients with public insurance were 9% less likely to be prescribed ACE-I/ARB therapy. Most
differences by insurance status were attenuated after adjusting for the site providing care. For example, whereas
uninsured patients with left ventricular dysfunction and CAD were less likely to receive ACE-I/ARB therapy (unad-
justed RR: 0.88; 95% CI: 0.84 to 0.93), this difference was eliminated after adjustment for site (adjusted RR:
0.95; 95% CI: 0.88 to 1.03; p  0.18).
Conclusions Within this national outpatient cardiac registry, uninsured patients were less likely to receive evidence-based
medications for CAD. These disparities were explained by the site providing care. Efforts to reduce treatment
differences by insurance status among cardiac outpatients may additionally need to focus on improving the
rates of evidence-based treatment at sites with high proportions of uninsured patients. (J Am Coll Cardiol
2013;61:1069–75) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.058Patients without healthcare insurance have worse health
outcomes (1–3). Uninsured patients are less likely to receive
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access to care, and the extent to
which these differences are ex-
plained by the site providing care,
have not been well studied.
Coronary artery disease (CAD)
would be the ideal condition in
which to examine these questions.
CAD is a prevalent and burden-
some disease, and there is compel-
ling evidence for the use of second-
ary prevention in this population
(8,9). Secondary prevention includes
antiplatelet and lipid-lowering
agents in CAD patients, beta-
blocker therapy in patients with a
history of myocardial infarction
(MI), angiotensin-converting en-
zyme inhibitors (ACE-Is) or angio-
tensin II receptor blockers (ARBs)
in MI patients with left ventricular
systolic dysfunction (LVSD) and/or
diabetes, and thienopyridine therapy in patients with recent
percutaneous coronary intervention (PCI) with a drug-eluting
stent (10–12).
Accordingly, this study examined the association between
insurance status and physicians’ adherence with providing
evidence-based treatments within the PINNACLE (Practice
Innovation and Clinical Excellence) registry of the NCDR
(National Cardiovascular Data Registry). This recently devel-
oped prospective, U.S. outpatient cardiac registry provides a
unique opportunity to examine the quality of outpatient cardiac
care in contemporary practices in the United States. This study
examined whether differences in medication treatment by
insurance status exist in CAD patients, and the extent to which
these differences are explained by the site providing care. The
analyses were focused on long-term medication treatments that
are performance measures or key indicators of CAD care
quality. Based on prior studies (13–15), it was hypothesized
that: 1) there is a gradient in care quality, with publicly insured
patients less likely to receive evidence-based care for CAD
than privately insured patients, and with uninsured patients
having the lowest rate of compliance with these therapies;
and 2) much of the treatment difference by insurance status
is due to the site at which patients receive their care. If
differences by insurance status exist and are provider based,
the findings from this study may provide important insights
into improving the quality of cardiovascular care for patients
without insurance.
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Participants and Study Design
The NCDR PINNACLE Registry (previously known as
the Improving Continuous Cardiac Care [IC3] program), is
ponsored by the American College of Cardiology (ACC)
nd is the first national outpatient cardiac registry in the
nited States (16,17). Details on the PINNACLE Registry
ave been described previously (16). Briefly, this U.S.
uality-improvement registry prospectively collects data on
ardiac disease from outpatient practices, with a focus on
erformance measures for the 4 most common cardiovas-
ular conditions: CAD, hypertension, heart failure, and
trial fibrillation. Each quarter, practices are provided re-
orts of treatment rates for a series of cardiac performance
easures (16). Both academic and private practices are en-
ouraged to participate, and physicians or representatives from
ach practice are required to complete a series of educational
raining sessions on data collection, system requirements, and
eport interpretation prior to data submission. To ensure data
uality, routine data checks are performed by both the ACC
nd the primary analytic center, the Mid America Heart
nstitute (Kansas City, Missouri).
This study evaluated data from 136,204 patients with
bstructive CAD from 30 practices that were enrolled in the
INNACLE Registry from January 1, 2009, through De-
ember 31, 2009. Site characteristics are provided in Online
able 1. CAD was defined as a history of MI or coronary
evascularization with PCI or coronary artery bypass sur-
ery. Patients’ characteristics and treatment data were in-
luded only from the baseline enrollment visit to avoid
ver-representation of patients with multiple visits. Because
he primary endpoint was the association between insurance
tatus and quality of cardiovascular care indicators, and
ecause most patients age 65 years or older are covered by
edicare, the analyses were restricted to data from those
atients under 65 years of age in PINNACLE (75,310
xcluded). A total of 80 patients did not have information
n health insurance available and were additionally ex-
luded. The final study cohort comprised 60,814 patients.
ealth Insurance and Study Outcomes
ealth insurance status was documented from the practices’
edical records and categorized as private, public, or no
nsurance. Private health insurance included either fee-for-
ervice or health maintenance organization plans, while public
ealth insurance included Medicare, Medicaid, Indian Health
ervice, and Veterans Administration/Military Health Care.
atients with both private and public types of health insurance
ere classified as having private insurance.
Five quality-of-care indicators for CAD care were evaluated.
hese indicators included the following ACC Foundation/
merican Heart Association/American Medical Associa-
ion–Physician Consortium for Performance Improvement
erformance measures related to medication use in CAD
atients: use of antiplatelet and lipid-lowering therapy in
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March 12, 2013:1069–75 Health Insurance and Quality of Care in CADpatients with CAD; beta-blocker therapy in patients with a
history of MI; and ACE-I/ARB therapy in patients with
LVSD and/or diabetes (18). In addition, the study exam-
ined ongoing treatment with thienopyridine therapy (i.e.,
clopidogrel) in patients with a drug-eluting stent after PCI
in the previous year (Online Table 2) (10). For each of these
5 measures, medication treatment rates by insurance status
were determined.
Treatment rates for a given performance measure were
calculated by dividing the number of patients prescribed a
medication for a given quality indicator by the number of
patients eligible to receive that medication. Patients were
considered eligible if they met the established inclusion
riteria for that measure and did not have a medical (e.g., a
igh risk for bleeding for antiplatelet or thienopyridine
herapy or medication allergy) or a personal (e.g., a patient’s
references) contraindication for that measure. Because
ligibility requirements for the 5 indicators differed, a
atient could be excluded from analyses of some indicators
ut included in others.
ther Patient Characteristics
he PINNACLE Registry collects from patients’ medical
ecords information on a number of other patient characteris-
ics, including demographics (age, sex, and race, which was
ategorized as white, black, or other) and comorbidities,
ncluding hypercholesterolemia, hypertension, peripheral arterial
isease, diabetes mellitus, history of CAD, history of unstable or
table angina, chronic heart failure, atrial fibrillation, history of
troke or transient ischemic attack, history of systemic embolism,
nd obesity (body mass index,30 kg/m2). In addition, informa-
ion on tobacco use (current, former, or never) and vital signs
blood pressure and heart rate) was collected.
tatistical Analysis
atients’ characteristics were compared by insurance status (no
nsurance, public insurance, or private insurance) using analyses
f variance for continuous variables and chi-square tests for
ategorical variables, as appropriate. Rates of medication treat-
ent for the 5 quality-of-care indicators for CAD were
ompared by insurance status using chi-square tests.
Separate modified Poisson regression models were con-
tructed to examine the association of insurance status with
ach of the 5 quality-of-care indicators for CAD. A series of
nadjusted models was constructed first, followed by hierar-
hical models with site as a random effect. In each model, the
ate of treatment was the dependent variable and insurance
tatus was the independent variable, with private insurance as
he reference category. The unadjusted and adjusted estimates
f effect for insurance status were compared between each of
he performance outcomes. The adjusted models were adjusted
or site only: 1) to evaluate the extent to which associations
etween health insurance status and treatment of CAD were
xplained by variations in performance at the site at which
atients received care; and 2) because other attributes of (atients should not influence the decision to treat, as patients
ith contraindications were excluded.
All analyses were performed using SAS version 9.2 (SAS
nstitute Inc., Cary, North Carolina), with all tests being 2-sided
nd a p value 0.05 considered to be statistically significant.
esults
f 60,814 patients, 5,716 (9.4%) patients were uninsured
nd 11,962 (19.7%) patients had public insurance, whereas
3,136 (70.9%) were privately insured. Compared with
atients having either public or private insurance, uninsured
atients were younger and were more frequently female.
ninsured patients were more likely to present with a
istory of chronic heart failure but also had fewer comor-
idities (including hypercholesterolemia, hypertension, pe-
ipheral arterial disease, diabetes mellitus, CAD, stable
ngina, stroke, and atrial fibrillation) (Table 1).
Treatment rates for the 5 quality-of-care indicators are
resented in Table 2. Treatment rates for the overall
opulation ranged from 70.6% to 94.6%, with the lowest
ate (70.6%) noted for thienopyridine therapy in patients
ho underwent PCI with DES in the previous year, and the
ighest rate (94.6%) noted for the use of lipid-lowering
rugs in patients with CAD. Uninsured patients were less
ikely to receive beta-blocker therapy after MI compared to
hose who had private health insurance (73.3% vs. 80.5%;
nadjusted RR: 0.91; 95% CI: 0.87 to 0.95; p  0.001)
Tables 2 and 3). Similarly, they were less likely to be treated
ith lipid-lowering drugs (89.3% vs. 94.9%; unadjusted RR:
.94; 95% CI: 0.92 to 0.96; p  0.001), and patients with
VSD and/or diabetes were less likely to be prescribed
CE-I/ARB therapy (66.7% vs. 75.5%; unadjusted RR:
.88; 95% CI: 0.84 to 0.93; p  0.001). There were no
ifferences in treatment rates between uninsured patients
nd those with private insurance for antiplatelet and thien-
pyridine therapy. In contrast, there were no meaningful
ifferences in treatment rates between patients with public
nd private insurance except for ACE-I/ARB therapy in
atients with LVSD and/or diabetes (69.1% for public
nsurance vs. 75.5% for private insurance; unadjusted RR:
.91; 95% CI: 0.89 to 0.94; p  0.001).
Figure 1 displays the relationship between a practice’s
roportion of uninsured patients and the practice’s compli-
nce rate with 2 performance measures: beta-blocker ther-
py after MI and ACE-I/ARB therapy in patients with
AD and LVSD. There was a notable inverse relationship
etween the 2 rates, suggesting that the lower rate of
reatment in uninsured patients may be influenced by the
ractice at which they received care. To account for this, in
ierarchical models adjusting for site only, differences in
reatment by insurance status were largely attenuated.
fter adjustment, uninsured patients had similar rates of
reatment with beta-blocker therapy (adjusted RR: 0.97;
5% CI: 0.93 to 1.01; p  0.14), lipid-lowering therapy
adjusted RR: 0.98; 95% CI: 0.95 to 1.00; p  0.08), and
aM
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to 1.03; p  0.18) (Table 3). Differences in ACE-I/ARB
therapy in patients with public insurance were also
Baseline Characteristics, by Healthcare Insurance Status*Table 1 Baseline Characteristics, by Healthcare Insurance Sta
Characteristic
No Insura
(n  5,716 [
Age, yrs 52.2 10.0 49.6 1
Female 27,296 (45.1) 2,755 (48
Race*
White 22,674 (81.9) 2,213 (83
Black/African American 4,672 (16.9) 399 (15
Hispanic 509 (1.0) 59 (1.
Asian 287 (1.0) 27 (1.
Native American/Native Alaskan 99 (0.4) 10 (0.
Native Hawaiian/Pacific Islander 57 (0.2) 8 (0.
Insurance payer type
Medicare (fee for service) 8,174 (13.4) 0
Medicaid 4,586 (7.5) 0
State-specific plan (non-Medicaid) 3,323 (5.5) 0
Military health care 1,270 (2.1) 0
Medicare (managed care) 611 (1.0) 0
Indian Health Service 18 (0.1) 0
Comorbidities
Hypertension 40,322 (66.3) 3,437 (60
Hypercholesterolemia 33,658 (55.3) 3,005 (52
Coronary artery disease 25,268 (41.5) 2,417 (42
Diabetes mellitus 11,716 (19.3) 994 (17
Atrial fibrillation/flutter 5,950 (9.8) 502 (8.
Chronic heart failure 5,425 (8.9) 631 (11
Stable angina 2,212 (3.6) 160 (2.
Peripheral arterial disease 1,781 (2.9) 137 (2.
Stroke/TIA 1,357 (2.2) 110 (1.
Unstable angina 570 (0.9) 52 (0.
Systemic embolism 180 (0.3) 21 (0.
Tobacco use
Never 26,938 (50.8) 2,576 (50
Former 16,423 (31.0) 1,494 (29
Current 9,679 (18.2) 992 (19
Blood pressure, mm Hg
Systolic 126.9 18.2 126.0 1
Diastolic 78.5 11.1 78.5 1
Values are mean  SD or n (%). *Among the 29,630 patients with available data on race.
TIA  transient ischemic attack.
Overview of Treatment Rates for CAD Quality-of-Care Indicators, byTable 2 Overview of Treatment Rates for CAD Quality-of-Care I
Quality-of-Care Indicator
Overall Population
(n  60,814)
Beta-blocker after MI 6,418/8,032 (79.9)
ACE-I/ARB in CAD with LVSD and/or diabetes‡ 6,293/8,612 (73.1)
Lipid-lowering drug in CAD 21,376/22,607 (94.6)
Antiplatelet agent in CAD† 18,966/20,866 (90.9)
Thienopyridine agent in PCI patients with DES 1,357/1,922 (70.6)
Values are n/N (%). *Treatment rates related to CAD medications (18) and the prescription of a t
thienopyridine, or a combination of aspirin and dipyridamole. ‡Defined as left ventricular ejectionACE-I/ARB  angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; CAD  coro
I  myocardial infarction; PCI  percutaneous coronary intervention.attenuated but not eliminated (adjusted RR: 0.95; 95%
CI: 0.92 to 0.98; p  0.003). Finally, the results of the
nalyses were essentially unchanged when public insur-
Insurance Status
p Value)
Public
(n  11,962 [19.7%])
Private
(n  43,136 [70.9%])
52.3 10.1 52.5 9.7 0.001
5,820 (48.8) 18,721 (43.6) 0.001
3,763 (73.0) 16,698 (83.9) 0.001
1,334 (25.9) 2,939 (14.8) 0.001
98 (0.9) 352 (1.0) 0.14
43 (0.8) 217 (1.1) 0.27
17 (0.3) 72 (0.4) 0.93
8 (0.2) 41 (0.2) 0.40
5,137 (42.9) 3,037 (7.0) 0.001
3,836 (32.1) 750 (1.7) 0.001
3,249 (27.2) 74 (0.2) 0.001
1,100 (9.2) 170 (0.4) 0.001
534 (4.5) 77 (0.2) 0.001
4 (0.1) 14 (0.1) 0.39
7,752 (64.8) 29,133 (67.5) 0.001
5,873 (49.1) 24,780 (57.4) 0.001
5,049 (42.2) 17,802 (41.3) 0.09
3,162 (26.4) 7,560 (17.5) 0.001
1,069 (8.9) 4,379 (10.2) 0.001
1,289 (10.8) 3,505 (8.1) 0.001
425 (3.6) 1,627 (3.8) 0.001
567 (4.7) 1,077 (2.5) 0.001
368 (3.1) 879 (2.0) 0.001
126 (1.1) 392 (0.9) 0.34
33 (0.3) 126 (0.3) 0.56
0.001
4,235 (44.4) 20,127 (52.4)
2,801 (29.3) 12,128 (31.6)
2,513 (26.3) 6,174 (16.1)
127.2 19.2 126.9 17.8 0.001
78.2 11.5 78.6 10.9 0.002
lthcare Insurance Status*tors, by Healthcare Insurance Status*
No Insurance
 5,902 [9.1%])
Public Insurance
(n  13,419 [20.7%])
Private Insurance
(n  45,418 [70.1%])
661/902 (73.3) 1,156/1,418 (81.5) 4,601/5,712 (80.5)
468/702 (66.7) 1,602/2,320 (69.1) 4,223/5,590 (75.5)
811/2,029 (89.3) 4,311/4,499 (95.8) 15,254/16,079 (94.9)
256/1,380 (91.0) 4,332/4,834 (89.6) 13,378/14,652 (91.3)
82/117 (70.1) 193/262 (73.7) 1,082/1,543 (70.1)
ridine in patients who underwent PCI with DES in the previous year (10). †May include aspirin, a
n 40%.tus*
nce
9.4%]
1.2
.5)
.5)
.1)
2)
0)
4)
3)
.1)
.6)
.3)
.4)
8)
.0)
8)
4)
9)
9)
4)
.9)
.5)
.6)
9.1
1.8Heandica
(n
1,
1,
hienopy
fractionary artery disease; DES  drug-eluting stent(s); LVSD  left ventricular systolic dysfunction;
A
c
w
u
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public insurance (e.g., Veterans Administration, Medic-
aid) (Online Tables 3 and 4).
Discussion
In this large national outpatient registry, treatment rates with
evidence-based medications in CAD patients differed by in-
surance status. Uninsured patients were less likely to have been
treated with lipid-lowering therapy for CAD, beta-blockers
after MI, and ACE-I/ARB therapy in those with LVSD
and/or diabetes. In contrast, patients with public health insur-
ance generally had rates of treatment similar to those with
private health insurance. Notably, most of these differences were
eliminated after adjusting for the site at which patients received
care, which suggests that treatment differences at the patient level
were largely explained by lower rates of medication treatment
at sites with higher proportions of uninsured patients. These
findings indicate that existing disparities by insurance status in
the treatment of patients with evidence-based medications for
CAD are likely to persist unless targeted interventions are
developed to improve the quality of care at practices with large
numbers of uninsured patients.
Although prior studies have reported on the underuse of
medications for primary cardiovascular disease prevention
(4,19–21) and poor adherence to evidence-based secondary
prevention therapies (22), this large national study exam-
ined differences in rates of treatment with evidence-based
therapies for CAD patients by health insurance coverage.
Such differences in treatment rates are important to identify,
as the evidence for optimal secondary prevention in CAD
Association Between Insurance Status andTreatment Rates for CAD Quality-of-Care IndicatTable 3 Associatio Between Insu ce StaTreatment Rates for CAD Quality-of
Quality Indicator
Beta-blocker therapy after MI
No insurance
Public insurance
ACE-I/ARB therapy in CAD with LVSD and/or diabetes†
No insurance
Public insurance
Lipid-lowering drugs in CAD
No insurance
Public insurance
Antiplatelet therapy in CAD‡
No insurance
Public insurance
Thienopyridine therapy in PCI patients with DES
No insurance
Public insurance
*Including the 4 American College of Cardiology Foundation/American
Performance Improvement performance measures related to CAD
underwent PCI with DES in the previous year (10). The unadjusted asso
is represented (relative risk [RR], 95% confidence interval [CI]), as w
insurance is the reference group for all quality indicators. †LVSD deno
aspirin, thienopyridine, or combination of aspirin and dipyridamole.
Abbreviations as in Table 2.has been established through a number of randomized tclinical trials and summarized as both clinical practice
guidelines and performance measures (8,9). Although prior
research has found that uninsured patients are treated less
aggressively than are insured patients during hospital stays
for MI (23), these findings document that treatment
disparities exist in the outpatient setting as well. Until
recently, gaps in the care of outpatients had been difficult
to evaluate, as large registry studies of outpatient cardiac
care had not been possible. With the emergence of the
NCDR PINNACLE Registry, uninsured patients were
found less likely to be treated with certain medications
unrelated to antiplatelet therapy known to reduce mor-
bidity and mortality in those with CAD (12,24 –26).
Lower rates of treatment with evidence-based medica-
tions for CAD in uninsured patients reflect not only poor
care but also cost-inefficient care. Providing free coverage of
evidence-based treatment (antiplatelet therapy, beta-blocker
therapy, lipid-lowering drugs, ACE-I/ARB agents) after an
MI is associated with improved survival and lower rates of
acute coronary syndromes in low-income patients (22).
mong Medicare beneficiaries, providing full coverage for
ombination pharmacotherapy after an MI was associated
ith greater functional life expectancy and lower resource
se (27), while other work has reported similar findings on
ree coverage of ACE-Is among patients with diabetes (28).
ore recently, in a randomized clinical trial, patients with
I randomized to free coverage of their cardiovascular
edications had lower rates of total major vascular events
nd revascularization procedures (29).
Given the high risk for cardiovascular events in pa-
nd
Indicators*
Unadjusted Adjustment for Site
(95% CI) p Value RR (95% CI) p Value
0.87–0.95) 0.0001 0.97 (0.93–1.01) 0.14
0.98–1.04) 0.40 1.02 (0.98–1.05) 0.33
0.84–0.93) 0.0001 0.95 (0.88–1.03) 0.18
0.89–0.94) 0.0001 0.95 (0.92–0.98) 0.003
0.92–0.96) 0.0001 0.98 (0.95–1.00) 0.08
1.00–1.02) 0.006 1.00 (0.99–1.01) 0.61
0.98–1.01) 0.72 0.99 (0.96–1.01) 0.35
0.97–0.99) 0.0001 0.98 (0.96–1.00) 0.07
0.88–1.13) 0.99 0.97 (0.85–1.10) 0.64
0.97–1.14) 0.22 1.04 (0.98–1.10) 0.19
Association/American Medical Association–Physician Consortium for
tions (18) and the prescription of thienopyridine in patients who
between insurance status and treatment rates for the quality indicator
the effect of the sequential adjustments for site variability. Private
ventricular ejection fraction40%. ‡Antiplatelet therapy may includeors*tu a
-Care
RR
0.91 (
1.01 (
0.88 (
0.91 (
0.94 (
1.01 (
1.00 (
0.98 (
1.00 (
1.05 (
Heart
medica
ciation
ell as
tes leftients with a history of obstructive CAD, the develop-
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Health Insurance and Quality of Care in CAD March 12, 2013:1069–75ment of mechanisms to ensure that uninsured patients
have access to care and medication treatment would
improve the quality of overall care without necessarily
increasing overall treatment costs. For instance, directing
uninsured CAD patients to prescription-assistance pro-
grams may help to facilitate their access to evidence-
based medications. Improving providers’ awareness about
patients’ ability to afford care, and promoting the exis-
tence of such programs, will be important factors in
ensuring that patients have access to them (30).
Many patients in the United States currently do not have
Figure 1 Uninsured Patients by Practice and
Adherence to Quality-of-Care Indicators
Relationship between a practice’s proportion of uninsured patients and its pre-
scription rate of (A) beta-blocker therapy after myocardial infarction and (B)
ACE-I/ARB therapy in coronary artery disease with left ventricular systolic dys-
function. ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin II
receptor blocker.adequate outpatient follow-up for CAD (31). It is well-documented that uninsured individuals have many unmet
healthcare needs and experience substantial cost barriers to
seeking care (6,32). In addition, patients may also be woefully
underinsured. These are patients who, despite having health-
care insurance, may avoid or delay needed health care due to
the perceived high costs associated with accessing care (e.g.,
high copayments and insurance deductibles) (33). This study
did not document difficulties with access to care (e.g., under-
insurance) but reported on treatment differences by insurance
status among those with access to care. Therefore, these
findings are likely an underrepresentation of the real challenges
associated with access to high-quality outpatient care among
the uninsured and underinsured.
Study limitations. Treatment rates among practices par-
ticipating in the PINNACLE Registry may differ from
those outside of PINNACLE; therefore, the findings may
not be generalizable to all U.S. practices. Because patient
exclusions from each performance measure were assigned by
practices themselves, some of these assignments may have
been inaccurate. If such misclassifications were differential at
the practice level, some of the observed disparities in medica-
tion treatment may have been attributable to differences in
coding for medication exceptions. The results presented in this
study are not generalizable to patients age 65 years or older
who are covered by Medicare. Detailed information on the
degree of coverage for patients, including pharmaceutical
coverage, was unavailable, which may have further explained
the variation in prescription rates. Although this analysis was
based on physicians’ prescription of medication treatments,
treatment adherence, which has also been documented in prior
studies to differ by insurance status (34,35), was not examined.
Conclusions
Uninsured patients with CAD were less likely to receive
treatment with evidence-based medications, such as lipid-
lowering therapy, beta-blocker therapy after MI, and ACE-I/
ARB therapy in patients with LVSD and/or diabetes. These
treatment differences by insurance status were mainly ex-
plained by the site at which patients received care. To
reduce existing treatment disparities by insurance status in
the outpatient setting, efforts to expand insurance access
should be pursued, and quality-of-care interventions will
need to target practices with high proportions of uninsured
patients in order to optimize access to evidence-based CAD
treatment for all CAD patients.
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APPENDIX
For details on the study sites, quality-of-care indicators, and more detailed
analysis for quality-of-care indicators by types of insurance, please see the
supplementary tables in the online version of this article.
